Authors: Varun Kumar, Kavita Singh
Abstract: The rapid development of novel drug formulations has revolutionized modern healthcare, offering enhanced therapeutic benefits and improved patient outcomes. However, evaluating the cost-effectiveness of these innovations is critical to ensure sustainable healthcare systems. This paper aims to analyze the economic impact of novel drug formulations, comparing them to traditional therapies. Through a comprehensive review of current literature and case studies, we will present key findings on cost-effectiveness, supported by tables and figures illustrating cost-benefit analyses, patient outcomes, and healthcare system impacts.
Keywords: Cost-effectiveness, Novel drug formulations, Modern healthcare, Biologics, Biosimilars, Targeted therapies, Incremental cost-effectiveness ratio (ICER), Quality-adjusted life year (QALY), Healthcare economics, Patient outcomes.
Full Issue
| View or download the full issue | PDF 18-32 |